JPRN-UMIN000011126已完成2 期
A randomized Phase II study of Carboplatin + Pemetrexed followed by Pemetrexed versus Carboplatin+Pemetrexed followed by Erlotinib in patients with advanced Non-squamous and Non- Small Cell Lung Cancer without EGFR mutations - LOGIK1301
ung Oncology Group in Kyushu, Japan (LOGIK)0 个研究点目标入组 120 人开始时间: 2013年7月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Active severe comorbidity disease. 2) Interstitial pneumonia or pulmonary fibrosis on chest CT scans. 3) Patients with symptomatic Brain metastases. 4) Active concomitant malignancy. 5) History of grave drug allergic reaction. 6) Pregnant or breast-feeding females. 7) Unstable psychic disorder. 8) Accepted continuous use of steroid. 9) Administration of folic acid and vitamin B12 is not received. 10) Diagnosed EML4-ALK fusion gene positive. 11) Inappropriate patients for this study judged by the physicians.
研究者
相似试验
已完成
2 期
A randomized Phase II study of Carboplatin + Pemetrexed followed by Pemetrexed versus Carboplatin+Pemetrexed followed by Erlotinib in patients with advanced Non-squamous and Non- Small Cell Lung Cancer with EGFR sensitive mutations LOGIK1302JPRN-UMIN000011174ung Oncology Group in Kyushu, Japan (LOGIK)65
暂停
2 期
A phase II study comparing carboplatin plus pemetrexed followed by maintenance pemetrexed with pemetrexed in elderly patients with advanced epidermal growth factor receptor non-squamous non-small-cell lung cancer (LCEN1301)JPRN-UMIN000013387ung Cancer Experts Network (LCEN)76
已完成
2 期
A Multicenter phase II study of Carboplatin/Pemetrexed/Bevacizumab in First-Line Treatment of Elderly Patients with Advanced Non-squamous and Non-small Cell Lung canceron-squamous non-small cell lung cancerJPRN-UMIN000011095Kurume University School of Medicine42
已完成
2 期
A phase II study of carboplatin plus pemetrexed followed by gefitinib for stage IIIB/IV non-small cell lung cancer with EGFR mutationon-small cell lung cancer with EGFR mutationJPRN-UMIN000003354Kanagawa Cancer Center60
已完成
3 期
A phase III study comparing carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L CBDCA/PEM vs DOC Phase III)Elderly patients with advanced non-squamous non-small-cell lung cancerJPRN-UMIN000011460Japan Clinical Oncology Group (JCOG)430